Rate My Professor Peter Middleton

Middleton's contributions to the field are evidenced by his extensive publication record, particularly in cystic fibrosis therapies. He co-authored the study "Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele" in the New England Journal of Medicine (2019), which has 2371 citations. Other highly cited papers include "Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis" (Nature Medicine, 1995; 989 citations), "VX-445-Tezacaftor-Ivacaftor in patients with Cystic Fibrosis and one or two Phe508del alleles" (New England Journal of Medicine, 2018; 857 citations), "A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a Phe508del CFTR mutation: a phase 2 randomised trial" (The Lancet Respiratory Medicine, 2014; 595 citations), and "Non–invasive liposome–mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice" (Nature Genetics, 1993; 539 citations). These publications focus on gene therapy and CFTR modulator treatments for cystic fibrosis. Middleton's research also addresses bronchiectasis, including contributions to the Australian Bronchiectasis Registry and studies such as "Cystic fibrosis modulator therapy can reverse cystic bronchiectasis" (Respirology Case Reports, 2023). His work supports advancements in the diagnosis and management of respiratory diseases.